Sanofi focuses on oncology pipeline, shares watched by international investors

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 20:00.

Sanofi (FR0000120578) remains a key large cap in European pharmaceuticals. The Paris-based group is listed in Paris on Euronext and is part of the Stoxx Europe 600 Health Care index, drawing continuous attention from international investors.

Pipeline focus in oncology and immunology

Sanofi continues to highlight its growth focus on oncology and immunology, including assets addressing multiple myeloma and inflammatory diseases, alongside vaccines and established specialty care franchises. The company positions these areas as key drivers of its medium-term earnings profile.

The French group has communicated plans in recent quarters to prioritize high-value research and development projects while managing legacy portfolios and streamlining non-core assets in order to support profitability and cash generation.

Position among European pharma peers

As one of the largest European drug makers, Sanofi is often compared with peers such as Novartis and AstraZeneca in terms of pipeline breadth, innovation focus and capital allocation between R&D, dividends and potential share repurchases. Its diversified portfolio in vaccines, rare diseases and specialty care supports a broad earnings base.

Analysts frequently assess Sanofi shares on valuation metrics relative to European and global pharmaceutical peers, monitoring earnings revisions, regulatory milestones and clinical data updates that can move sentiment on the stock.

How Sanofi generates its revenue

Sanofi generates most of its revenue from prescription medicines, vaccines and specialty care treatments, including therapies for rare diseases, oncology and immunology. Additional income streams arise from consumer health products and partnerships or licensing agreements with other pharmaceutical companies.

Where the stock trades today

Sanofi stock trades primarily on Euronext Paris, where it is part of major benchmarks followed by global investors; the current share price and valuation metrics are monitored closely on that venue throughout each trading day.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.